ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Mesenchymal Stem Cells Ameliorate Sjögren Disease by Suppressing B Cells through the Pik3cb/Akt/mTOR Pathway
Zhifang Wu 1
Chunning Wang 2
Linsha Ma 3
Dengsheng Xia 1
1. Beijing Stomatological Hospital & School of Stomatology, Capital Medical University, Beijing, China
2. School of Stomatology, Capital Medical University, Beijing, China
3. Beijing Friendship Hospital, Capital Medical University,, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Mesenchymal stem cells (MSCs) hold great promise for the treatment of Sjögren disease (SjD) owing to their potent immunomodulatory capacity. However, the precise molecular mechanism by which MSCs regulate the characteristic B cell dysregulation in SjD remains largely unknown. In this study, we found that Pik3cb expression was significantly upregulated in submandibular glands (SMGs) of NOD mice, a well-established SjD model. Notably, genome-wide microarray profiling identified Pik3cb as a pivotal mediator of the therapeutic efficacy of allogeneic MSCs in NOD mice, suggesting it plays a role in SjD pathogenesis and treatment. Systematic investigation of the role of Pik3cb in MSC therapy and B cell regulation revealed that MSC administration and pharmacological inhibition of Pik3cb (using TGX-221) significantly attenuated SjD progression. This attenuation was characterised by the robust suppression of B cell responses, including activation, chemotaxis, plasma cell differentiation, and antibody production. Both interventions effectively restored salivary secretion and alleviated lymphocytic infiltration and fibrosis in the SMGs. Concurrently, a favourable shift in the cytokine profile was observed, with diminished pro-inflammatory cytokines (IL-4, IL-6, IFN-γ) and upregulated anti-inflammatory factors (IL-10, TGF-β1) in the SMGs and spleens. Additionally, Pik3cb overexpression in B cells abrogated the MSC-induced therapeutic benefits, confirming the specificity of Pik3cb as a target. Finally, mechanistic studies revealed that MSC efficacy was correlated with Pik3cb suppression, resulting in the subsequent downregulation of Akt/mTOR signaling. In conclusion, this study provides mechanistic evidence that MSC therapy mitigates B cell dysfunction in SjD through the Pik3cb/Akt/mTOR pathway. Furthermore, our data identified Pik3cb as a hitherto unrecognized molecular target in SjD pathogenesis, suggesting that its pharmacological inhibition may represent a promising complementary therapeutic avenue for SjD meriting further investigation.
Summary
Keywords
autoimmunity 5, B cells 2, mesenchymal stem cells 3, phosphoinositide 3-kinase β4, Sjögren disease 1
Received
06 December 2025
Accepted
19 February 2026
Copyright
© 2026 Wu, Wang, Ma and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhifang Wu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.